Objectives: Progression-free survival of first-line targeted therapy greatly influences the survival of patients with metastatic renal cell carcinoma. We evaluated whether post-treatment inflammatory markers and lactate dehydrogenase levels had impacts on progression-free survival prediction in addition to those of conventional predictors. Methods: Two hundred and fifteen patients whose tumors were clear cell type and in whom firstline targeted therapies could be continued for >1 month were evaluated. Pretreatment clinical factors, pathological factors and laboratory data 1 month after targeted therapy initiation-including inflammatory markers (neutrophil count, neutrophil-to-lymphocyte ratio and C-reactive protein) and lactate dehydrogenase-were reviewed. To identify progression-free survival predictors, multivariate analyses were done. Results: The 1-year progression-free survival rate was 47%. Female gender, Karnofsky performance status <80%, time from diagnosis to systemic treatment <12 months, pretreatment C-reactive protein >3.0 mg/dl and post-treatment neutrophil-to-lymphocyte ratio >3.0 were independent predictors for progression-free survival. In contrast, neither C-reactive protein increase nor neutrophil-to-lymphocyte ratio increase after targeted therapy initiation were independent predictors. Pretreatment lactate dehydrogenase, post-treatment lactate dehydrogenase and lactate © The Author(s) 2018. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Introduction
The prognosis of patients with metastatic renal cell carcinoma (mRCC) has been improved by the initiation of the targeted era (1) . To lengthen patients' survival, we need to use effective targeted agents (TAs) sequentially, controlling metastatic disease as long as possible with each TA. Progression-free survival (PFS) of first-line targeted therapy (TT) greatly influences the overall survival (OS) of patients with mRCC (2) . The first-line TA is generally selected according to guidelines for renal cancer treatment, but at this time it is impossible to choose the best first-line TA for an individual patient prior to the initiation of TT. Although the pretreatment selection of a suitable TA is difficult, we may be able to judge the suitability of each selected agent after the first-line TT initiation by adding changes of laboratory data (e.g., inflammatory markers and markers of cancer metabolism) after TT initiation to conventional pretreatment predictors of progression.
Several pretreatment and post-treatment factors have been reported to be PFS predictors (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) . If we can predict PFS immediately after the first-line TT initiation by using factors easy to examine, we can easily use them in daily clinical practice. Pretreatment inflammatory markers such as C-reactive protein (CRP) (11) (12) (13) and neutrophil-to-lymphocyte ratio (NLR) (15) are reportedly predictors for PFS and/or OS in patients with mRCC. And decreased CRP levels at the time of maximum effect indicated by computed tomography (CT) after TT initiation are also reportedly predictors for PFS and OS (14) . NLR decline 6 weeks after the TT initiation is associated with longer PFS in patients with mRCC (16) . These findings make early changes of inflammatory markers attractive PFS predictor candidates. In addition to these inflammatory markers, lactate dehydrogenase (LDH), one of the Memorial Sloan kettering Cancer Center (MSKCC) risk factors (17) , plays an important role in tumor metabolism (18) and possibly decreases in response to TT. We speculated that the change of LDH level after the TT initiation was a potential PFS predictor.
In the present study, we evaluated whether post-treatment inflammatory markers and LDH levels after the first-line TT initiation had impacts on PFS prediction in addition to those of conventional predictors for progression.
Patients and methods
After institutional review board approval, a total of seven Japanese institutions provided data on 325 consecutive patients who received first-line TT for mRCC. Of these patients, 14 whose clinical data were insufficient were excluded (Fig. 1 ). Of the remaining 311 patients, 215 whose tumors were clear cell type and in whom first-line TT could be continued for >1 month were finally selected for further analyses.
The pretreatment assessments of clinical characteristics and blood data were collected just before TT initiation, while posttreatment blood data were collected 4 ± 1 weeks following treatment induction. Eighty patients had received prior cytokine therapy. The median follow-up of the entire cohort was 20.6 months (interquartile range, 9.1-32.1).
Patients were followed every 2-4 weeks after the initiation of any type of TTs. Follow-up consisted of history evaluation, physical examination, routine blood work and chest radiography. Radiographic evaluations for CT were generally performed every 2-3 months, while additional CTs and elective bone scans were performed when clinically indicated.
PFS was defined as the time from treatment initiation to the date of disease progression or was censored at the last radiological confirmation of disease control, when TT was discontinued because of adverse events or patients' hope or death. OS was defined as the time from treatment initiation to the date of death from any cause or was censored at the last follow-up. We obtained outcome and survival data retrospectively. Clinical factors evaluated are shown in Table 1 . Laboratory values were standardized according to the institutional upper limit of normal (ULN). The evaluated laboratory data and the cut-off values are shown in Table 2 . Anemia was defined as a hemoglobin level ≤13 g/dl in men or ≤11.5 g/dl in women (17) , and thrombocytosis was defined by a platelet count ≥350 000/mm 3 (19) . ULN was used as a cut-off for neutrophil count. Corrected calcium levels up to 10 mg/dl were considered normal (17). 1.5 × ULN was used as the cut-off value for pretreatment LDH (pre-LDH) (17) and post-treatment LDH (post-LDH) levels. The NLR was calculated by dividing the absolute neutrophil count by the absolute lymphocyte count (20) . For NLR and CRP, the values best discriminating between good and poor survival were determined by testing all possible cut-off values within the central 85% of the distribution of values. Then, pretreatment NLR (pre-NLR) elevation was defined as pre-NLR >3.7 and post-treatment NLR (post-NLR) elevation was defined as post-NLR >3.0. Pretreatment CRP (pre-CRP) elevation was defied as pre-CRP >3.0 mg/dl and post-treatment CRP (post-CRP) elevation was defined as post-CRP >1.5 mg/dl. The results are presented as means ± standard deviations. Survival curves were estimated using the Kaplan-Meier method, and differences between them were assessed using the log-rank test. To evaluate the impact of inflammatory marker dynamics on PFS in detail (especially, CRP dynamics and NLR dynamics), the patients were grouped into five groups (≥50% decrease, 30-50% decrease, 0-30% decrease, 0-20% increase, >20% increase) and KaplanMeier curves were made. To identify predictors of PFS, univariate and multivariate analyses were performed using the Cox proportional hazards model. To minimize confounding among the factors, multivariate analysis was done by using the backward stepwise selection method.
The predictive ability of each risk model in the study population was evaluated using the c (concordance)-index proposed by Harrell et al. (21) . Differences between groups were regarded to be significant when P < 0.05. Statistical analyses were performed with R Statistical Language v.2.9 (R Foundation for Statistical Computing, Vienna, Austria) and JMP 12 (SAS Institute, Tokyo, Japan).
Results
Patients' clinical characteristics are listed in Table 1 . MSKCC risk criteria were favorable in 62 patients, intermediate in 122, poor in 17 and not determined in 14. Nephrectomy was done for 184 patients and percutaneous needle biopsy was done for the diagnosis in 31 patients. Six TAs were used as first-line TT. Tyrosine kinase inhibitors (TKIs) were used for 205 patients and mammalian target of rapamycin (mTOR) inhibitors for 10 patients. Metastatic sites that more than 5% of all patients had are listed in the table, and these were used in univariate analysis. Median PFS and OS of all patients were 11.8 and 42.7 months, respectively (Fig. 2) .
Kaplan-Meier curves evaluating conventional predictors for survival [gender, sarcomatoid differentiation, Karnofsky performance status (KPS) and time from diagnosis to TT initiation] are shown in Supplementary Fig. S1 . Patients with pre-NLR >3.7, post-NLR >3.0, pre-CRP >3.0 mg/dl and post-CRP >1.5 mg/dl had significantly worse PFS than their respective counterparts did. In contrast, NLR decline and CRP decline 1 month after the TT initiation were not significantly associated with PFS (Fig. 3 ). In addition, the patients were further divided to five groups by degree of CRP change or degree of NLR change (≥50% decrease, 30-50% decrease, 0-30% decrease, 0-20% increase, >20% increase) to evaluate the impact of inflammatory marker dynamics on PFS prediction. There was neither significant impact of degree of CRP change ( Supplementary Fig. S2A ) nor degree of NLR change ( Supplementary Fig. S2B ) on PFS after treatment initiation. Regarding LDH, patients with elevated pre-LDH and elevated post-LDH had significantly worse PFS than their respective counterparts did. In contrast, LDH decline 1 month after the TT initiation was not significantly associated with PFS ( Supplementary Fig. S3 ). Pretreatment neutrophil count was significantly associated with PFS, but neutrophil count decline was not.
Univariate analysis showed that 13 factors were significantly associated with PFS (Table 3) . Although elevated pretreatment neutrophil count, elevated pre-and post-NLR, elevated pre-and post-CRP, and elevated pre-and post-LDH were significant factors, LDH decline, decline in neutrophil count, CRP decline and NLR decline 1 month after the TT initiation were not significant factors. In multivariate analysis, female gender, KPS < 80%, time from diagnosis to systemic treatment <12 months, pre-CRP >3.0 and post-NLR >3.0 were independent predictors for PFS (Table 4) . When all patients were stratified by these five factors into three groups (0 risk vs. 1 or 2 risks vs. 3 or more risks), there were significant differences in PFS rates between the groups (P < 0.0001) (Fig. 4) . The median time to progression was 27.6 months for 0 risk, 10.0 months for one or two risks, and 2.8 months for three or more risks. Furthermore, there were also significant differences in OS rates between the three groups (P < 0.0001). The median OS was 58.5 months for 0 risk, 33.5 months for one or two risks, and 7.6 months for three or more risks.
Our novel risk model using the five indices was compared with the widely used risk models, the MSKCC model (17) and the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model (22) . Regarding the MSKCC models using the five indices of time from diagnosis to treatment <12 months, poor KPS, anemia, hypercalcemia and high LDH, the median PFS after treatment initiation were 29.8 months in the favorable-risk group, 9.9 months in the intermediate-risk group and 2.8 months in the poorrisk group (Supplementary Fig. S4A ) (P < 0.001). The median OS were not reached in the favorable-risk group, 29.6 months in the intermediate-risk group and 9.8 months in the poor-risk group (Supplementary Fig. S4B ) (P < 0.001). Regarding the IMDC models Post-treatment data were examined at 1 month after TT initiation. 
Discussion
In the present study, we evaluated whether we could predict the PFS of patients with metastatic clear cell RCC effectively after the firstline TT initiation by using post-treatment inflammatory markers and LDH level at 1 month in addition to conventional prognostic factors. In multivariate analysis, post-NLR >3.0 was one of the independent predictors for PFS, and we could establish risk stratification by using five independent predictors, including pre-CRP and post-NLR. This risk stratification was also significantly associated with OS. The absolute value of a patient's post-NLR appeared to be more important for PFS prediction than did the NLR decline 1 month after TT. The time to progression of the first-line TT greatly influences the survival of patients with mRCC (2). If we can know the suitability of the first-line TA early after the TT initiation, this information may be clinically useful. For a patient with a high risk for progression, for example, we may be able to change the first-line TA immediately to seek other effective TAs or immuno-oncology drugs, or be able to do follow-up examinations at a shorter interval to detect progression earlier. Previously reported post-treatment predictors for PFS were mostly examined at 2 months or later. Few reports showed useful PFS predictors that can be determined within 2 months after the TT initiation. Nakaigawa et al. reported that increased glucose accumulation assessed by FDG-PET/CT at 4 (A) Risk stratification using five predictive factors for progression. When we stratified 215 patients to three groups according to the number of risk factors (0 risk vs. 1 or 2 risks vs. 3 risks or more), there were significant differences in PFS rates between the groups (P < 0.0001). The median time to progression was 27.6 months in low risk, 10.0 months in intermediate risk and 2.8 months in poor risk. (B) Survival curve stratified by three risk groups. There were also significant differences in OS rates between the three groups (P < 0.0001). The median overall survival was 58.5 months in low risk, 33.5 months in intermediate risk and 7.6 months in poor risk. OS, overall survival.
weeks after TT initiation was associated with shorter PFS in mRCC patients treated with TKIs (5). Templeton et al. reported that decrease of NLR at 6 weeks after the TT initiation was significantly associated with longer PFS, longer OS and higher response rate (16) . We examined the efficacies of the absolute values of post-treatment inflammatory markers and LDH and the decrease in these values at 1 month after the TT initiation by multivariate analysis to identify independent PFS predictors. We found the absolute value of post-NLR was one of the independent predictors for PFS. Our stratification only included simple factors and appeared to be clinically useful for decision-making and for counseling mRCC patients treated by the first-line TTs. Previous reports have shown that radiological findings such as early tumor shrinkage (3, 4) , increased glucose accumulation (5), MASS criteria (6), CT texture (7) and Choi criteria (8, 9) , immunohistochemical markers (10) and inflammatory markers such as CRP and NLR (11) (12) (13) (14) (15) (16) are significant predictors for PFS. We simply used posttreatment laboratory data in addition to pretreatment factors and did not use radiological changes after the TT initiation or immunohistochemical markers. Pre-CRP is reportedly a predictor for PFS and/or OS in mRCC patients treated with TT (11) (12) (13) , and CRP decline after the TT initiation is also reportedly a predictor for PFS in mRCC patients (14) . Furthermore, pre-NLR is a significant predictor for PFS and OS after TT initiation in patients with metastatic RCC (15) , and NLR decline in response to TT is reportedly associated with longer PFS and longer OS in patients with mRCC (16) . In the present study, we tried to determine the most powerful predictor for PFS among various inflammatory markers which have been reported as PFS predictors. We first had an idea that PFS could be predicted effectively by adding inflammatory marker dynamics to the risk model for PFS prediction. In the present study, however, absolute values of post-NLR and post-CRP appeared to be more important in PFS prediction than did decline in those makers at 1 month after TT initiation. Slight declines in inflammatory makers may have no significant impact on PFS in patients with highly elevated pretreatment levels of inflammatory markers. And slight increases in inflammatory markers may have minimal impact on PFS in patients with very low pretreatment levels of inflammatory markers. To evaluate the impact of inflammatory marker dynamics on PFS prediction in detail, the patients were further divided to five groups by degree of CRP change or degree of NLR change ( Supplementary Fig. S2A and B) . These results indicated that neither CRP dynamics nor NLR dynamics appeared to have significant impact on PFS after treatment initiation when inflammatory markers were measured 1 month after treatment initiation. Because inflammatory marker levels may change easily due to various factors including adverse events which are likely to be occurred in early times after TT initiation, 1 month after TT initiation may not be an appropriate time to evaluate the impact of inflammatory marker dynamics on PFS.
In the present study, we also evaluated the efficacy of LDH values and LDH change as a candidate for PFS predictors. LDH is one of the MSKCC prognostic factors (17) . A large amount of lactate is produced during aerobic glycolysis in cancer cells (23) , and LDH is a glycolysis enzyme that catalyzes the conversion of pyruvate into lactate and could potentially be increased in tumor metabolism. So if renal cancer cells are damaged by TT, serum LDH levels possibly decrease in response to TT. We thus evaluated the absolute values of LDH and the LDH decline as a candidate for independent PFS predictors. In this study, elevated pre-LDH and elevated post-LDH were associated with PFS in univariate analysis but not in multivariate analysis. LDH decline after TT initiation was not associated with PFS even in univariate analysis.
In the present study, female gender was one of the independent predictors for PFS. This study included only patients with clear cell RCC, and in this situation female gender was an independent predictor for PFS. When we compared patients' characteristics between female and male patients, the difference between the two groups was minimal (Supplementary Table S1 ). In a previous report, female patients were significantly associated with shorter PFS in patients with advanced clear cell RCC who were treated with sunitinib or pazopanib (10) . In contrast, male gender was reportedly an independent predictor for worse OS in mRCC patients treated with second-line TKI after interferon-α (15) . In that study, gender was not significantly associated with PFS even in univariate analysis. In our study, female gender was one of the independent predictors for PFS but there was no significant OS difference between female and male patients (P = 0.6257). Further investigation of the gender difference for PFS prediction will be needed.
This study has several limitations. First, it is limited by its retrospective nature, as well as its heterogeneous group of patients with a short median follow-up. To minimize the heterogeneity, we evaluated only patients with clear cell RCC. Second, various kinds of TAs were used and the starting dosages were not unified because of the retrospective nature of the present study. Third, this study excluded mRCC patients whose TTs were discontinued due to early tumor progression, deterioration of general condition or adverse events. Our risk model may be applicable for patients in whom TT can be continued for more than 1 month.
Conclusions
Integration of elevated post-NLR 1 month after the first-line TT initiation with pretreatment factors may lead to the establishment of effective predictive models for disease progression in patients with metastatic clear cell RCC who receive TTs. The absolute value of post-NLR 1 month after the first-line TT initiation appeared to be more important for PFS prediction than did the NLR decline 1 month after TT initiation.
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